Michael J. Eblan - Concepedia

Author

Michael J. Eblan

University of North Carolina at Chapel Hill

Also Known As

M. Eblan, M. J. Eblan, M.J. Eblan, McKinnon, Karen P., Michael Eblan, Michael J Eblan, Michael J. Eblan, Michael Joseph Eblan, The University of North Carolina at Chapel Hill University Libraries, Tracton, Gregg

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill National Human Genome Research Institute Duke Medical Center Duke University Hospital University of North Carolina Hospitals

About

Michael J. Eblan is an author at University of North Carolina at Chapel Hill specializing in medicine, oncology, and neuropathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.7K
2	Engineering	2	2	698
3	Health Sciences	2	2	459
4	Public Health	1	1	67
5	Social Sciences	1	1	50

Michael J. Eblan

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease E. Sidransky, Mike A. Nalls, Jan Aasly, New England Journal of Medicine	2009	2.1K
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy Yuanzeng Min, Kyle C. Roche, Shaomin Tian, Nature Nanotechnology NanoparticlesNanomedicineTumor ImmunologyAntigen-capturing NanoparticlesEngineering	2017	667
Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy Kyle Wang, Michael J. Eblan, Allison M. Deal, Journal of Clinical Oncology Heart FailureDose-escalation TrialsCardiovascular ToxicityRadiation MedicineOncology	2017	419
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders Özlem Göker-Alpan, Benoit I. Giasson, Michael J. Eblan, Neurology Lysosomal ProteinImportant Risk FactorGeneticsGenetic EpidemiologyMolecular Biology	2006	227
Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer Kyle Wang, Kevin A. Pearlstein, Nicholas D. Patchett, Radiotherapy and Oncology MedicineHeart Dosimetric AnalysisCardiac ToxicityBronchial NeoplasmDose-escalation Trials	2017	123
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease Shira G. Ziegler, Michael J. Eblan, Usha Gutti, Molecular Genetics and Metabolism Chinese SubjectsMendelian DisorderGeneticsParkinson DiseasePathology	2007	107
Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis Shivani Sud, Jordan A. Holmes, Michael J. Eblan, Gynecologic Oncology Endometrial Cancer OutcomesHealth Care DisparityEpidemiology Of CancerReproductive HealthGynecology	2017	67
Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease Özlem Göker-Alpan, Edythe Wiggs, Michael J. Eblan, The Journal of Pediatrics Neurodegenerative DiseasesNeuropsychologyAlzheimer's DiseaseMedicineDementia	2008	50
Toward a better understanding of task demands, workload, and performance during physician-computer interactions Łukasz Mazur, Prithima Mosaly, Carlton Moore, Journal of the American Medical Informatics Association	2016	47
Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated With Definitive Radiation: Dosimetric Analysis and Clinical Implications Michael J. Eblan, Michael N. Corradetti, John N. Lukens, International Journal of Radiation OncologyBiologyPhysics Dosimetric AnalysisRadiation MedicineRadiation TherapyMedicineDefinitive Radiation	2012	40

Page 1